Analysis reveals FGL1 may serve as a biomarker for gastric cancer, influencing invasion and suggesting new therapeutic signal pathways.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: